FindMyKOL
Clinical trialNCT00882024CompletedPhase 2Interventional

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

NCT00882024 is a phase 2 interventional trial sponsored by Nuon Therapeutics, Inc.. As of 21 Nov 2026, it is completed. It studies Placebo and Tranilast in Active Rheumatoid Arthritis. The registry lists an enrollment of 250 participants at 32 sites in 8 countries. The registry lists a start date of 31 Mar 2009 and a primary completion date of 31 Dec 2010.

SponsorNuon Therapeutics, Inc.Enrollment250Active Rheumatoid Arthritis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00882024
FieldValue
Registry IDNCT00882024
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorNuon Therapeutics, Inc.
Enrollment250
Registered sites32
Countries8
ConditionsActive Rheumatoid Arthritis
DrugsPlacebo and Tranilast
Start31 Mar 2009
Primary completion31 Dec 2010
Study completion31 Dec 2010
Last update posted6 Jan 2011

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate whether tranilast at two different dosages compared to placebo is effective in patients with active RA when added to continuing methotrexate (MTX) therapy.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Arizona, United States2 sites
  • Facility name not stated

    Mesa

  • Facility name not stated

    Paradise Valley

California, United States2 sites
  • Facility name not stated

    La Jolla

  • Facility name not stated

    San Diego

Florida, United States1 site
  • Facility name not stated

    Aventura

Maryland, United States1 site
  • Facility name not stated

    Frederick

Michigan, United States1 site
  • Facility name not stated

    Lansing

North Carolina, United States1 site
  • Facility name not stated

    Hickory

Pennsylvania, United States1 site
  • Facility name not stated

    Duncansville

Germany6 sites
  • Facility name not stated

    Hamburg

  • Facility name not stated

    Ludwigsfelde

  • Facility name not stated

    Naumburg

  • Facility name not stated

    Osnabrück

  • Facility name not stated

    Ratingen

  • Facility name not stated

    Wiesbaden

Argentina4 sites
  • Facility name not stated

    Capital Federal, Buenos Aires

  • Facility name not stated

    Luján, Buenos Aires

  • Facility name not stated

    Quilmes, Buenos Aires

  • Facility name not stated

    Rosario, Santa Fe Province

Czechia4 sites
  • Facility name not stated

    Brno-Bohunice

  • Facility name not stated

    Ostrava-Hlucin

  • Facility name not stated

    Prague

  • Facility name not stated

    Zlín

Mexico4 sites
  • Facility name not stated

    Mexicali, Estado de Baja California

  • Facility name not stated

    Guadalajara, Jalisco

  • Facility name not stated

    Morelia, Michoacán

  • Facility name not stated

    Obregón, Sonora

Bulgaria2 sites
  • Facility name not stated

    Plovdiv

  • Facility name not stated

    Sofia

Serbia2 sites
  • Facility name not stated

    Belgrade

  • Facility name not stated

    Niška Banja

United Kingdom1 site
  • Facility name not stated

    London

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichigan: 1 siteMI1New YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 sitePA1New JerseyNJConnecticutCTCalifornia: 2 sitesCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizona: 2 sitesAZ2UtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboTranilast
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00882024

Each answer restates registry values shown on this page.

What is NCT00882024?

NCT00882024 is a phase 2 interventional trial sponsored by Nuon Therapeutics, Inc.. It studies Placebo and Tranilast in Active Rheumatoid Arthritis.

Who leads NCT00882024?

The registry names Michael Kitt, MD (study director, Nuon Therapeutics, Inc.) as the overall official.

Where does NCT00882024 run?

The registry lists 32 sites in 8 countries. Most sites are in these countries: United States (9), Germany (6) and Argentina (4).

Which drugs does NCT00882024 study?

The registered drug and biological interventions are Placebo and Tranilast.

When did NCT00882024 end?

The registry lists a primary completion date of 31 Dec 2010 and a study completion date of 31 Dec 2010. The sponsor last updated the record on 6 Jan 2011.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.